PTC Therapeutics (PTCT) Lowered to Buy at ValuEngine

ValuEngine cut shares of PTC Therapeutics (NASDAQ:PTCT) from a strong-buy rating to a buy rating in a research note released on Tuesday.

A number of other equities analysts also recently issued reports on PTCT. Credit Suisse Group initiated coverage on PTC Therapeutics in a report on Thursday, July 19th. They issued an outperform rating and a $49.00 price target for the company. Citigroup reiterated a buy rating and issued a $50.00 price objective (up previously from $35.00) on shares of PTC Therapeutics in a research note on Tuesday, July 24th. Bank of America boosted their price objective on PTC Therapeutics from $27.00 to $31.00 and gave the company an underperform rating in a research note on Tuesday, July 31st. Barclays boosted their price objective on PTC Therapeutics from $40.00 to $43.00 and gave the company an equal weight rating in a research note on Wednesday, August 8th. Finally, JPMorgan Chase & Co. boosted their price objective on PTC Therapeutics to $51.00 and gave the company a neutral rating in a research note on Friday, September 28th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of Buy and an average price target of $46.25.

PTCT traded down $2.54 on Tuesday, reaching $33.76. The company’s stock had a trading volume of 613,911 shares, compared to its average volume of 682,113. The company has a quick ratio of 4.18, a current ratio of 2.73 and a debt-to-equity ratio of 0.37. The company has a market capitalization of $1.84 billion, a price-to-earnings ratio of -16.71 and a beta of 2.21. PTC Therapeutics has a fifty-two week low of $14.87 and a fifty-two week high of $52.95.

PTC Therapeutics (NASDAQ:PTCT) last announced its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($1.06) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.66). The business had revenue of $53.59 million during the quarter, compared to analyst estimates of $70.56 million. PTC Therapeutics had a negative net margin of 30.61% and a negative return on equity of 27.95%. The business’s revenue for the quarter was up 28.0% compared to the same quarter last year. During the same period last year, the company earned ($0.82) earnings per share. On average, equities analysts anticipate that PTC Therapeutics will post -1.92 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of PTCT. Meeder Asset Management Inc. purchased a new stake in PTC Therapeutics in the second quarter valued at approximately $137,000. Lourd Capital LLC purchased a new stake in shares of PTC Therapeutics during the third quarter worth approximately $202,000. Xact Kapitalforvaltning AB purchased a new stake in shares of PTC Therapeutics during the second quarter worth approximately $216,000. Quantitative Systematic Strategies LLC purchased a new stake in shares of PTC Therapeutics during the second quarter worth approximately $218,000. Finally, CAPROCK Group Inc. purchased a new stake in shares of PTC Therapeutics during the second quarter worth approximately $222,000. Institutional investors own 85.72% of the company’s stock.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for the treatment of rare disorders. The company offers Translarna (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy in ambulatory patients; and Emflaza (deflazacort) for treating Duchenne muscular dystrophy.

Featured Article: How Do You Calculate Return on Investment (ROI)?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for PTC Therapeutics (NASDAQ:PTCT)

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply